Misplaced Pages

Motexafin lutetium: Difference between revisions

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
Browse history interactively← Previous editContent deleted Content addedVisualWikitext
Revision as of 09:18, 13 October 2011 editCheMoBot (talk | contribs)Bots141,565 edits Updating {{chembox}} (no changed fields - added verified revid - updated 'ChemSpiderID_Ref', 'DrugBank_Ref', 'UNII_Ref', 'ChEMBL_Ref', 'ChEBI_Ref', 'KEGG_Ref', 'StdInChI_Ref', 'StdInChIKey_Ref', 'ChEBI_Ref') per [[WP:CHEMVALID|Chem/Drugbox validat...← Previous edit Latest revision as of 00:37, 17 June 2022 edit undoInnerstream (talk | contribs)Autopatrolled, Extended confirmed users4,081 editsmNo edit summary 
(12 intermediate revisions by 11 users not shown)
Line 1: Line 1:
{{chembox {{chembox
| verifiedrevid = 449584968 | verifiedrevid = 455343846
|ImageFile=Motexafin lutetium.png | ImageFile=Motexafin lutetium.svg
|ImageSize=200px | ImageSize=200px
|IUPACName= | IUPACName=
|OtherNames=Antrin; Lu texaphyrin; Lu-Tex; Lutetium texaphyrin; Lutrin; Optrin; PCI 0123 | OtherNames=Antrin; Lu texaphyrin; Lu-Tex; Lutetium texaphyrin; Lutrin; Optrin; PCI 0123
|Section1={{Chembox Identifiers |Section1={{Chembox Identifiers
| CASNo_Ref = {{cascite|correct|??}}
| CASNo=246252-04-0 | CASNo=246252-04-0
⚫ | PubChem=3081907
| UNII_Ref = {{fdacite|correct|FDA}}
⚫ | SMILES=CC()=O.CCC1=C2C(/C=C3N=C(/C=N/C4=CC(OCCOCCOCCOC)=C(OCCOCCOCCOC)C=C4/N=C/C(C(C)=C/5CCCO)=()C5=C/2)C(C)=C\3CCCO)=C1CC
| UNII = 0V38NF6N89
⚫ | PubChem=3081907
⚫ | SMILES=CC()=O.CCC1=C2C(/C=C3N=C(/C=N/C4=CC(OCCOCCOCCOC)=C(OCCOCCOCCOC)C=C4/N=C/C(C(C)=C/5CCCO)=()C5=C/2)C(C)=C\3CCCO)=C1CC
}} }}
|Section2={{Chembox Properties |Section2={{Chembox Properties
| C=52 | H=72 | Lu=1 | N=5 | O=14 | C=52 | H=72 | Lu=1 | N=5 | O=14
| Appearance= | Appearance=
| Density= | Density=
| MeltingPt= | MeltingPt=
| BoilingPt= | BoilingPt=
| Solubility= | Solubility=
}} }}
|Section3={{Chembox Hazards |Section3={{Chembox Hazards
| MainHazards= | MainHazards=
| FlashPt= | FlashPt=
| AutoignitionPt =
| Autoignition=
}} }}
}} }}
Line 29: Line 32:
It is a photosensitiser for use in ] to treat skin conditions and superficial cancers. It is a photosensitiser for use in ] to treat skin conditions and superficial cancers.


It has also been tested for use in ] (photodynamic treatment of diseased arteries).<ref>, 2002</ref> It has also been tested for use in ] (photodynamic treatment of diseased arteries).<ref> {{webarchive|url=https://web.archive.org/web/20110716075826/http://www2.prnewswire.com/cgi-bin/stories.pl?ACCT=104&STORY=%2Fwww%2Fstory%2F09-25-2002%2F0001806282&EDATE= |date=2011-07-16 }}, 2002</ref>


It is photoactivated by 732 nm light which allows greater depth of penetration.<ref>http://findarticles.com/p/articles/mi_qa3931/is_200909/ai_n42040200/pg_9/ Porphyrin and Nonporphyrin Photosensitizers in Oncology: Preclinical and Clinical Advances in Photodynamic Therapy Photochemistry and Photobiology, Sep/Oct 2009. by O'Connor, Aisling E, Gallagher, William M, Byrne, Annette T </ref> It is photoactivated by 732&nbsp;nm light which allows greater depth of penetration.<ref>http://findarticles.com/p/articles/mi_qa3931/is_200909/ai_n42040200/pg_9/ Porphyrin and Nonporphyrin Photosensitizers in Oncology: Preclinical and Clinical Advances in Photodynamic Therapy Photochemistry and Photobiology, Sep/Oct 2009. by O'Connor, Aisling E, Gallagher, William M, Byrne, Annette T</ref>


==Clinical trials== ==Clinical trials==
Phase II clinical trials were in progress in 1999.<ref>, 1999</ref> Phase II clinical trials were in progress in 1999.<ref> {{Webarchive|url=https://archive.today/20120713142335/http://ir.pharmacyclics.com/releasedetail.cfm?ReleaseID=141812 |date=2012-07-13 }}, 1999</ref>


A phase I trial for ] reported in 2009.<ref>{{cite journal | pmid = 18676760 | year = 2008 | last1 = Patel | first1 = H | last2 = Mick | first2 = R | last3 = Finlay | first3 = J | last4 = Zhu | first4 = TC | last5 = Rickter | first5 = E | last6 = Cengel | first6 = KA | last7 = Malkowicz | first7 = SB | last8 = Hahn | first8 = SM | last9 = Busch | first9 = TM | title = Motexafin lutetium-photodynamic therapy of prostate cancer: Short and long term effects on PSA | volume = 14 | issue = 15 | pages = 4869–76 | doi = 10.1158/1078-0432.CCR-08-0317 | pmc = 2680073 | journal = Clinical cancer research : an official journal of the American Association for Cancer Research }}</ref> A phase I trial for ] reported in 2009.<ref>{{cite journal | pmid = 18676760 | year = 2008 | last1 = Patel | first1 = H | last2 = Mick | first2 = R | last3 = Finlay | first3 = J | last4 = Zhu | first4 = TC | last5 = Rickter | first5 = E | last6 = Cengel | first6 = KA | last7 = Malkowicz | first7 = SB | last8 = Hahn | first8 = SM | last9 = Busch | first9 = TM | title = Motexafin lutetium-photodynamic therapy of prostate cancer: Short and long term effects on PSA | volume = 14 | issue = 15 | pages = 4869–76 | doi = 10.1158/1078-0432.CCR-08-0317 | pmc = 2680073 | journal = Clinical Cancer Research }}</ref>


==References== ==References==
{{reflist}} {{reflist}}


⚫ {{Lutetium compounds}}



] ]
] ]

⚫ {{Lutetium compounds}}




Latest revision as of 00:37, 17 June 2022

Motexafin lutetium
Names
Other names Antrin; Lu texaphyrin; Lu-Tex; Lutetium texaphyrin; Lutrin; Optrin; PCI 0123
Identifiers
CAS Number
3D model (JSmol)
PubChem CID
UNII
SMILES
  • CC()=O.CCC1=C2C(/C=C3N=C(/C=N/C4=CC(OCCOCCOCCOC)=C(OCCOCCOCCOC)C=C4/N=C/C(C(C)=C/5CCCO)=()C5=C/2)C(C)=C\3CCCO)=C1CC
Properties
Chemical formula C52H72LuN5O14
Molar mass 1166.136 g·mol
Except where otherwise noted, data are given for materials in their standard state (at 25 °C , 100 kPa). checkY verify (what is  ?) Infobox references
Chemical compound

Motexafin lutetium is a texaphyrin, marketed as Antrin by Pharmacyclics Inc.

It is a photosensitiser for use in photodynamic therapy to treat skin conditions and superficial cancers.

It has also been tested for use in photoangioplasty (photodynamic treatment of diseased arteries).

It is photoactivated by 732 nm light which allows greater depth of penetration.

Clinical trials

Phase II clinical trials were in progress in 1999.

A phase I trial for prostate cancer reported in 2009.

References

  1. Pharmacyclics Announces Final Phase 1 Results of Antrin Phototherapy For Coronary Artery Disease Archived 2011-07-16 at the Wayback Machine, 2002
  2. http://findarticles.com/p/articles/mi_qa3931/is_200909/ai_n42040200/pg_9/ Porphyrin and Nonporphyrin Photosensitizers in Oncology: Preclinical and Clinical Advances in Photodynamic Therapy Photochemistry and Photobiology, Sep/Oct 2009. by O'Connor, Aisling E, Gallagher, William M, Byrne, Annette T
  3. Antrin Photoangioplasty Phase II Clinical Trial Patient Treated During Live Case Demonstration at TCT Archived 2012-07-13 at archive.today, 1999
  4. Patel, H; Mick, R; Finlay, J; Zhu, TC; Rickter, E; Cengel, KA; Malkowicz, SB; Hahn, SM; Busch, TM (2008). "Motexafin lutetium-photodynamic therapy of prostate cancer: Short and long term effects on PSA". Clinical Cancer Research. 14 (15): 4869–76. doi:10.1158/1078-0432.CCR-08-0317. PMC 2680073. PMID 18676760.
Lutetium compounds


Stub icon

This dermatologic drug article is a stub. You can help Misplaced Pages by expanding it.

Categories: